
    
      This is a safety study with an open-label part (2 groups), followed by a dose-ranging part
      evaluating safety and immunogenicity using a double-blind, sequential-group design with
      randomization and placebo-control within each of the 6 groups. Volunteers in each dose group
      will receive two IM injections at Day 0 and Month 1
    
  